SOURCE: Novo Nordisk A/S

November 17, 2008 08:36 ET

Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - November 17, 2008) - Novo Nordisk A/S - Share repurchase programme

On 15 August 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 1.7 billion in the period from 15 August 2008 to 19 December 2008.

Since the announcement as of 10 November 2008, the following transactions have been made under the programme:

                  Number of    Average      Transaction
                   shares   purchase price  value, DKK
Accumulated, last
announcement      3,376,500                  956,623,504
10 November 2008     50,000       307.8600    15,393,000
11 November 2008     50,000       304.0800    15,204,000
12 November 2008     50,000       305.3800    15,269,000
13 November 2008     50,000       297.9500    14,897,500
14 November 2008     50,000       297.2600    14,863,000
Accumulated under
the programme     3,626,500                1,032,250,004

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 83,305 B-shares in the period from 10 November 2008 to 14 November 2008. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 24,593,285 treasury shares, corresponding to 3.9% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:                 Investors:


Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
ekh@novonordisk.com    mlau@novonordisk.com

                       Hans Rommer
                       Tel: (+45) 4442 4765
                       hrmm@novonordisk.com

In North America:      Kasper Roseeuw Poulsen
Sean Clements          Tel: (+45) 4442 4471
Tel: (+1) 609 514 8316 krop@novonordisk.com
secl@novonordisk.com

Company Announcement no 75 / 2008

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2008. All rights reserved.

Contact Information